PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a ...

Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show ...

Over the past few years, Sanofi has increasingly upped its bet that vaccines and therapies based on messenger RNA (mRNA) technology could transform the drug industry. Now, the firm is going all in ...

During translation, multiple ribosomes travel along the nucleic acid chain to build polypeptides that become functional proteins. Occasionally, these molecular decoders pause on the mRNA, either ...

Translate Bio CEO Ronald C. Renaud Jr. discusses his company, its mRNA platform, and its partnership with Sanofi in COVID-19 and other diseases as a guest in September 2020 on “GEN Live,” GEN’s ...

PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) ...

In a recent study published in Nature, a group of researchers explored how the incorporation of N1-methylpseudouridine (1-methylΨ) into messenger ribonucleic acids (mRNAs) affects ribosomal ...

In a statement released Tuesday, Sanofi said it would acquire Translate Bio for $3.2 billion. Sanofi has been partnering with the company to develop an mRNA-based Covid vaccine, which rivals Pfizer, ...

Vaccines to prevent SARS-CoV-2 infection were not the first attempt at utilizing the promise of mRNA in a therapeutic setting. From the discovery of mRNA in the 1960s, many scientists, clinicians, and ...